Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921350985> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2921350985 abstract "574 Background: In multicenter randomized phase 2 study (FARETES) we showed that male patients with mRCC receiving targeted therapy had significantly less fatigue and better symptom control with testosterone undecanoate (T) (MASCC 2018, LBA004). Here we described exploratory endpoints in FARETES study. Methods: Sixty male patients with clear cell mRCC, normal PSA level, low testosterone level and no evidence of hypothyroidism receiving first-line sunitinib or pazopanib with fatigue were randomly assigned (1:1) to either T (Nebido, 1,000 mg) and targeted therapy or targeted therapy alone (control group). T was injected intramuscular deeply on Day 1 of a new treatment cycle. Exploratory endpoints included rate of adverse events (AE) of targeted therapy, duration of targeted therapy, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: As of the data cutoff on October 17, 2018, median (range) follow-up was 15.2 (9.9 -16.5) months. No unexpected toxicity of T was observed. Grade 3-4 targeted therapy-related AE occurred in 11 (37%) and 3 (10%) patients in the control group and T group, respectively. Discontinuation due to AE was observed in 3% (1/30) of patients in the T group and in 17% (5/30) of patients in the control group. ORR and PFS were significantly better in the T group (all P < 0.05, Table). Median OS was not reached in either group. Clinical trial information: NCT03379012. Conclusions: T therapy could decrease rate of serious AE of targeted therapy. Male mRCC patients receiving T had longer duration of targeted therapy, better PFS and ORR. Larger trials are needed to evaluate efficacy of T in this group of patients.[Table: see text]" @default.
- W2921350985 created "2019-03-22" @default.
- W2921350985 creator A5016973497 @default.
- W2921350985 creator A5048104251 @default.
- W2921350985 creator A5048397469 @default.
- W2921350985 creator A5056315263 @default.
- W2921350985 creator A5070988170 @default.
- W2921350985 creator A5084083056 @default.
- W2921350985 date "2019-03-01" @default.
- W2921350985 modified "2023-09-28" @default.
- W2921350985 title "Exploratory endpoints in a FARETES study of the efficacy of testosterone in metastatic renal cell carcinoma (mRCC) patients." @default.
- W2921350985 doi "https://doi.org/10.1200/jco.2019.37.7_suppl.574" @default.
- W2921350985 hasPublicationYear "2019" @default.
- W2921350985 type Work @default.
- W2921350985 sameAs 2921350985 @default.
- W2921350985 citedByCount "0" @default.
- W2921350985 crossrefType "journal-article" @default.
- W2921350985 hasAuthorship W2921350985A5016973497 @default.
- W2921350985 hasAuthorship W2921350985A5048104251 @default.
- W2921350985 hasAuthorship W2921350985A5048397469 @default.
- W2921350985 hasAuthorship W2921350985A5056315263 @default.
- W2921350985 hasAuthorship W2921350985A5070988170 @default.
- W2921350985 hasAuthorship W2921350985A5084083056 @default.
- W2921350985 hasConcept C126322002 @default.
- W2921350985 hasConcept C126894567 @default.
- W2921350985 hasConcept C143998085 @default.
- W2921350985 hasConcept C2777472916 @default.
- W2921350985 hasConcept C2777546739 @default.
- W2921350985 hasConcept C2779279991 @default.
- W2921350985 hasConcept C71924100 @default.
- W2921350985 hasConceptScore W2921350985C126322002 @default.
- W2921350985 hasConceptScore W2921350985C126894567 @default.
- W2921350985 hasConceptScore W2921350985C143998085 @default.
- W2921350985 hasConceptScore W2921350985C2777472916 @default.
- W2921350985 hasConceptScore W2921350985C2777546739 @default.
- W2921350985 hasConceptScore W2921350985C2779279991 @default.
- W2921350985 hasConceptScore W2921350985C71924100 @default.
- W2921350985 hasLocation W29213509851 @default.
- W2921350985 hasOpenAccess W2921350985 @default.
- W2921350985 hasPrimaryLocation W29213509851 @default.
- W2921350985 hasRelatedWork W2067663694 @default.
- W2921350985 hasRelatedWork W2080490390 @default.
- W2921350985 hasRelatedWork W2145805456 @default.
- W2921350985 hasRelatedWork W2293892298 @default.
- W2921350985 hasRelatedWork W2467423746 @default.
- W2921350985 hasRelatedWork W2515950316 @default.
- W2921350985 hasRelatedWork W2539641070 @default.
- W2921350985 hasRelatedWork W2573038150 @default.
- W2921350985 hasRelatedWork W2589184112 @default.
- W2921350985 hasRelatedWork W2590871439 @default.
- W2921350985 hasRelatedWork W2591165238 @default.
- W2921350985 hasRelatedWork W2604171410 @default.
- W2921350985 hasRelatedWork W2617974212 @default.
- W2921350985 hasRelatedWork W2785103248 @default.
- W2921350985 hasRelatedWork W2789662395 @default.
- W2921350985 hasRelatedWork W2890720594 @default.
- W2921350985 hasRelatedWork W2955631801 @default.
- W2921350985 hasRelatedWork W2964700594 @default.
- W2921350985 hasRelatedWork W2996164021 @default.
- W2921350985 hasRelatedWork W3121504883 @default.
- W2921350985 isParatext "false" @default.
- W2921350985 isRetracted "false" @default.
- W2921350985 magId "2921350985" @default.
- W2921350985 workType "article" @default.